2022
2021
2020
2019
2018
2017
2016
2015
1
2
3
→
»
Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results
Feb 14, 2022
Aytu BioPharma Completes $15 Million Debt Refinancing
Jan 31, 2022
Aytu BioPharma Appoints Mark Oki as Chief Financial Officer
Jan 4, 2022
Aytu BioPharma to Present at H.C. Wainwright BioConnect Conference
Jan 3, 2022
Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome
Dec 13, 2021
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome
Dec 8, 2021